Shots:
The NICE has issued FAD recommending Revestive (qd, SC) as a treatment option for patients with SBS aged ≥1yrs. who are in a stable condition following surgery to remove an abnormal bowel
The recommendation was based on the (STEPS) & (STEPS-2) trials to evaluate teduglutide in patients with parenteral nutrition-dependent SBS. The recommended dose of teduglutide is 0.05mg/kg body weight & will be given in ml of sol.
Teduglutide is the 1st disease-modifying treatment for SBS with intestinal failure & has the potential to improve the absorption of nutrients & fluid from the remaining intestine. SBS patients require parenteral support that can last up to 14hrs. a day, 7 days a wk.
Ref: PRNewswire | Image: Takeda
